Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
3.380
-0.090 (-2.59%)
At close: Oct 17, 2025, 4:00 PM EDT
3.285
-0.095 (-2.82%)
After-hours: Oct 17, 2025, 7:20 PM EDT
Onconetix Revenue
Onconetix had revenue of $106.49K in the quarter ending June 30, 2025, a decrease of -84.89%. This brings the company's revenue in the last twelve months to $1.33M, down -9.35% year-over-year. In the year 2024, Onconetix had annual revenue of $2.52M with 4,217.31% growth.
Revenue (ttm)
$1.33M
Revenue Growth
-9.35%
P/S Ratio
0.57
Revenue / Employee
$265,392
Employees
5
Market Cap
5.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.52M | 2.47M | 4,217.31% |
| Dec 31, 2023 | 58.47K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ONCO News
- 22 days ago - Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - GlobeNewsWire
- 22 days ago - Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement - GlobeNewsWire
- 26 days ago - Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM - GlobeNewsWire
- 3 months ago - Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - GlobeNewsWire
- 4 months ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 4 months ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
- 5 months ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
- 5 months ago - Onco-Innovations Uplists to Cboe Canada - Business Wire